Warm Autoimmune Hemolytic Anemia
Warm Autoimmune Hemolytic Anemia Market

Warm Autoimmune Hemolytic Anemia


Warm Autoimmune Hemolytic Anemia (wAIHA) is one of the most prevalent psychiatric disorders and has been projected by the World Health Organisation to be the leading cause of disease burden in high-income countries by 2032. Autoimmune hemolytic anemia (AIHA) is defined as the increased destruction of red blood cells (RBCs) in the presence of anti-RBC autoantibodies with or without complement activation. Autoantibodies are produced by both tissue and circulating self-reactive B lymphocytes, following cooperation with T helper lymphocytes.

 

Warm Autoimmune Hemolytic Anemia Epidemiology Segmentation in the 7MM


●    Total Prevalent Cases of Autoimmune Hemolytic Anemia

●    Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia

●    Type-specific Prevalent cases of Warm Autoimmune Hemolytic Anemia

●    Gender-specific Prevalence of Warm Autoimmune Hemolytic Anemia



Warm Autoimmune Hemolytic Anemia Epidemiological Insights Observed in the 7MM

(2021)


  • The total incident cases of Warm Autoimmune Hemolytic Anemia observed in the 7MM were observed to be 115K in the year 2021
  • The highest diagnosed Warm Autoimmune Hemolytic Anemia population accounting for 52.6K cases, was found in the United States in the year 2021
  • Amongst EU5, Germany accounted for 11.5K cases, whereas the total prevalent cases in France were 8.9K cases.
  • Japan accounted for 18K cases. 


Warm Autoimmune Hemolytic Anemia Market Insight


The market size of Warm Autoimmune Hemolytic Anemia in the 7MM was found to be approximately USD 540 Million in 2021.  


Warm Autoimmune Hemolytic Anemia Emerging Drugs


The emerging drugs in the Warm Autoimmune Hemolytic Anemia market are

●   Fostamatinib

●    APL-2

●    M281

●    BIVV009 (Sutimlimab)

●    Parsaclisib

●    Rilzabrutinib

●    Isatuximab

●    ANX005 and others


Warm Autoimmune Hemolytic Anemia Key Players 


The key players working in the Warm Autoimmune Hemolytic Anemia market are


  • Sanofi
  • Incyte Corporation
  • Johnsons & Johnson Pharmaceuticals
  • Apellis Pharmaceuticals, Inc.
  • Rigel Pharmaceuticals
  • Annexon and others